PDS Biotechnology Corporation (NASDAQ:PDSB - Get Free Report)'s stock price shot up 8.7% during trading on Wednesday . The stock traded as high as $1.25 and last traded at $1.25. 709,500 shares traded hands during mid-day trading, an increase of 49% from the average session volume of 477,041 shares. The stock had previously closed at $1.15.
Analysts Set New Price Targets
Several brokerages recently commented on PDSB. Wall Street Zen downgraded shares of PDS Biotechnology from a "hold" rating to a "sell" rating in a research note on Saturday, June 14th. HC Wainwright reaffirmed a "buy" rating and set a $13.00 price target on shares of PDS Biotechnology in a research note on Tuesday, July 1st.
View Our Latest Analysis on PDSB
PDS Biotechnology Stock Performance
The company has a debt-to-equity ratio of 0.29, a current ratio of 2.33 and a quick ratio of 2.33. The company's 50-day moving average price is $1.44 and its two-hundred day moving average price is $1.36. The company has a market capitalization of $53.94 million, a price-to-earnings ratio of -1.26 and a beta of 1.21.
PDS Biotechnology (NASDAQ:PDSB - Get Free Report) last posted its quarterly earnings results on Wednesday, May 14th. The company reported ($0.21) EPS for the quarter, topping analysts' consensus estimates of ($0.25) by $0.04. On average, equities research analysts anticipate that PDS Biotechnology Corporation will post -1.2 EPS for the current fiscal year.
Institutional Investors Weigh In On PDS Biotechnology
A number of large investors have recently bought and sold shares of the stock. Raymond James Financial Inc. bought a new position in shares of PDS Biotechnology in the fourth quarter valued at $26,000. Jane Street Group LLC bought a new position in shares of PDS Biotechnology in the fourth quarter valued at $58,000. Marshall Wace LLP lifted its stake in shares of PDS Biotechnology by 38.4% in the fourth quarter. Marshall Wace LLP now owns 39,024 shares of the company's stock valued at $64,000 after buying an additional 10,837 shares in the last quarter. Tempus Wealth Planning LLC lifted its stake in shares of PDS Biotechnology by 154.3% in the second quarter. Tempus Wealth Planning LLC now owns 47,800 shares of the company's stock valued at $64,000 after buying an additional 29,000 shares in the last quarter. Finally, Iron Gate Global Advisors LLC bought a new position in shares of PDS Biotechnology in the first quarter valued at $89,000. 26.84% of the stock is currently owned by institutional investors and hedge funds.
About PDS Biotechnology
(
Get Free Report)
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.
Further Reading
Before you consider PDS Biotechnology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PDS Biotechnology wasn't on the list.
While PDS Biotechnology currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access